

# 1 **Global Force-of-Infection Trends for Human *Taenia solium*** 2 **Taeniasis/Cysticercosis**

3

4 **Matthew A. Dixon<sup>1,2,3\*</sup>, Peter Winskill<sup>2</sup>, Wendy E. Harrison<sup>3,†</sup>, Charles Whittaker<sup>1,2</sup>, Veronika**  
5 **Schmidt<sup>4,5</sup>, Astrid Carolina Flórez Sánchez<sup>6</sup>, Zulma M. Cucunubá<sup>1,2,§</sup>, Agnes U. Edia-Asuke<sup>7</sup>, Martin**  
6 **Walker<sup>8</sup>, Maria-Gloria Basáñez<sup>1,2</sup>**

7 \* Corresponding author: [m.dixon15@imperial.ac.uk](mailto:m.dixon15@imperial.ac.uk)

8 1 Department of Infectious Disease Epidemiology and London Centre for Neglected Tropical Disease  
9 Research (LCNTDR), Faculty of Medicine, School of Public Health, Imperial College London, London  
10 W2 1PG, UK

11 2 MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology,  
12 Faculty of Medicine, School of Public Health, Imperial College London, London W2 1PG, UK

13 3 SCI Foundation, Edinburgh House, 170 Kennington Lane, London, SE11 5DP

14 4 Department of Neurology, Center for Global Health, Technical University Munich (TUM), Munich,  
15 Germany

16 5 Centre for Global Health, Institute of Health and Society, University of Oslo, Oslo, Norway

17 6 Grupo de Parasitología, Instituto Nacional de Salud, Bogotá, Colombia

18 7 Ahmadu Bello University, 810211, Zaria, Nigeria

19 8 Department of Pathobiology and Population Sciences and London Centre for Neglected Tropical  
20 Disease Research (LCNTDR), Royal Veterinary College, Hatfield AL9 7TA, UK

21 § Present address: Departamento de Epidemiología Clínica y Bioestadística, Facultad de Medicina,  
22 Pontificia Universidad Javeriana, Bogotá, Colombia

23 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

24

25 **Abstract**

26 Infection by *Taenia solium* poses a major burden across endemic countries. The World Health  
27 Organization (WHO) 2021–2030 Neglected Tropical Diseases roadmap has proposed that 30% of  
28 endemic countries achieve intensified *T. solium* control in hyperendemic areas by 2030.  
29 Understanding geographical variation in age-prevalence profiles and force-of-infection (Fol) estimates  
30 will inform intervention designs across settings.

31 Human taeniasis (HTT) and human cysticercosis (HCC) age-prevalence data from 16 studies in Latin  
32 America, Africa and Asia were extracted through a systematic review. Catalytic models, incorporating  
33 diagnostic performance uncertainty, were fitted to the data using Bayesian methods, to estimate rates  
34 of antibody (Ab)-seroconversion, infection acquisition and Ab-seroreversion or infection loss. HCC Fol  
35 and Ab-seroreversion rates were also estimated across 23 departments in Colombia from 28,100  
36 individuals.

37 Across settings, there was extensive variation in all-ages seroprevalence. Evidence for Ab-  
38 seroreversion or infection loss was found in most settings for both HTT and HCC and for HCC Ab-  
39 seroreversion in Colombia. The average duration until humans became Ab-seropositive/infected  
40 decreased as all-age (sero)prevalence increased. There was no clear relationship between the average  
41 duration humans remain Ab-seropositive and all-age seroprevalence.

42 Marked geographical heterogeneity in *T. solium* transmission rates indicate the need for setting-  
43 specific intervention strategies to achieve the WHO goals.

44

## 45 Introduction

46 The zoonotic cestode *Taenia solium* poses a substantial public health and economic challenge.  
47 Globally, *T. solium* is ranked as the foodborne parasitic infection contributing the highest number  
48 of disability-adjusted life-years (DALYs), an estimated 2.78 million DALYs in 2010 (Havelaar et al.,  
49 2015). Control and elimination of *T. solium* requires a One Health approach (Thomas et al., 2019;  
50 Braae et al., 2019) due to its complex multi-host life-cycle, involving infection with larval-stage  
51 cysticerci in the intermediate pig host (porcine cysticercosis, or PCC), infective stages (eggs) in the  
52 environment, and taeniasis (infection with the adult worm) in the definitive human host (human  
53 taeniasis, or HTT). When humans ingest *T. solium* eggs, establishment of cysticerci (human  
54 cysticercosis, or HCC) in the central nervous system results in neurocysticercosis (NCC).  
55 Neurocysticercosis is responsible for the major health burden associated with *T. solium*, causing  
56 approximately one third of epilepsy/seizure disorders in endemic settings (Gripper and Welburn,  
57 2017).

58 Current interventions target PCC through mass treatment of pigs with oxfendazole and their  
59 vaccination with TSOL18, and HTT through mass treatment of humans with praziquantel or  
60 niclosamide. These control strategies have proven efficacious in field studies (de Coster et al., 2018;  
61 Dixon et al., 2021), but to date no large-scale interventions have been rolled out as part of national  
62 Neglected Tropical Disease (NTD) programmes, and therefore their impact alone or in combination  
63 in different epidemiological settings remains poorly understood and/or modelled (CystiTeam,  
64 2019). The milestones proposed in the new World Health Organization (WHO) NTD 2021–2030  
65 roadmap (World Health Organization, 2020) focus on achieving intensified control in hyperendemic  
66 areas of 17 (27%) endemic countries. However, endemicity levels for *T. solium* have not been  
67 defined in terms of infection indicators and there exist limited data on the geographical distribution  
68 of *T. solium* prevalence at national scales. For other NTDs, pre-intervention levels of endemicity  
69 (according to infection prevalence, intensity, incidence or morbi-mortality) determine the

70 magnitude, duration and likely success of control efforts (NTD Modelling Consortium  
71 Onchocerciasis Group, 2019). Therefore, successful *T. solium* intervention strategies will require  
72 tailoring to local epidemiological and socio-economic conditions that determine the intensity of  
73 transmission and will likely be informed by age- and/or sex-dependent contact rates and mixing  
74 patterns in endemic settings (Dixon et al., 2021; CystiTeam, 2019, Welburn et al., 2015).

75 Global patterns in transmission rates have recently been explored for PCC by assessing the force-  
76 of-infection (Fol; the per-capita rate of infection acquisition) according to proposed endemicity  
77 levels (overall (sero)prevalence) and geography (Dixon et al., 2020). Estimates of antibody (Ab) and  
78 antigen (Ag) seroconversion (and seroreversion rates) for HCC have also been estimated from a  
79 small number of longitudinal surveys in Burkina Faso (Dermauw et al., 2018), Peru (Garcia et al.,  
80 2001)], Ecuador (Coral-Almeida et al., 2014) and Zambia (Mwape et al., 2013), demonstrating  
81 substantial geographic variation.

82 Age-prevalence profiles are not only useful for estimating Fol and (sero)reversion rates, but also to  
83 provide insight into processes driving epidemiological dynamics, such as immunological responses  
84 or heterogeneity in exposure which may explain abrupt changes in HCC seropositivity in older  
85 individuals or distinct prevalence peaks in younger ages for HTT prevalence, as observed in the  
86 Democratic Republic of the Congo (DRC) (Kanobana et al., 2011; Madinga et al., 2017). Specific age-  
87 prevalence profiles may also provide insight into whether age-targeted interventions may be  
88 appropriate in certain settings. This study, therefore, and for the first time systematically collates  
89 and reviews all HTT and HCC age-(sero)prevalence data available from the literature and from  
90 collaborators, and uses simple and reversible catalytic models to estimate the Fol and Ab-  
91 seroreversion/infection loss rates from cross-sectional surveys. The results improve our  
92 understanding of global variation in the epidemiology of *T. solium* and provide estimates of  
93 transmission rates, crucial for guiding the design of interventions. In addition, a country profile of

94 Fol estimates is presented at the sub-national level for Colombia to exemplify how detailed Fol  
95 analyses can help understand local epidemiological patterns.

96

## 97 **Results**

### 98 **Systematic review and study selection**

99 After title, abstract and full-text eligibility screening of 236 studies initially identified (01/11/2014  
100 to 02/10/2019), and 11 studies included in the Coral-Almeida et al. (2015) literature review, a total  
101 of 16 studies were included in the analysis (PRISMA flowchart; Supplementary File 1:  
102 Supplementary Figure S1), originating from South America ( $n = 4$ ), Africa ( $n = 8$ ) and Asia ( $n = 4$ )  
103 (Supplementary File 1: Supplementary Figure S2) and split by  $n = 4$  HTT and  $n = 15$  HCC surveys (full  
104 details in Supplementary File 1: Supplementary Table S1). Total sample sizes were 6,653 individuals  
105 (range 576–4,599; with individual age range of <1 to 96 years) across HTT surveys, which included  
106 three copro-Ag-based surveys and one Ab-based survey; 34,124 (125–29,360; cross-study age  
107 range of <1 to 95 years) across HCC-Ab surveys, and 12,934 (905–4,993; cross-study age range of  
108 <1 to 96 years) across HCC-Ag surveys. Observed (sero)prevalence ranged from 4.5% to 23.4% (95%  
109 confidence interval (CI) range: 3.0%–24.6%) for HTT surveys, 0.5%–38.7% (0.1%–41.6%) across  
110 HCC-Ab surveys, and 0.7%–21.7% (0.5%–24.5%) across HCC-Ag surveys.

111 Catalytic models (Figure 1; full details in Material and methods) were fitted to the thus extracted  
112 (sero)prevalence data using a Bayesian framework that integrates uncertainty in diagnostic  
113 sensitivity and specificity from prior (published) information (Supplementary File 1: Supplementary  
114 Table S1). The Fol parameters of acquisition ( $\lambda$ ) and reversion/loss ( $\rho$ ) (for antibody datasets:  $\lambda_{sero}$   
115 and  $\rho_{sero}$ ; for antigen datasets:  $\lambda_{inf}$  and  $\rho_{inf}$ ) were estimated for each dataset. The deviance  
116 information criterion (DIC) (Spiegelhalter et al., 2002) was used to compare individually- and  
117 jointly-fitted catalytic models.

118 We defined hyperendemic transmission settings as those with all-age *observed* HTT  
119 (sero)prevalence of  $\geq 3\%$  and all-age *observed* HCC (sero)prevalence of  $\geq 6\%$ . Studies with  
120 (sero)prevalence values below these were defined as endemic transmission settings. These  
121 putative endemicity definitions were defined following a literature review of studies referring to  
122 “hyper” or “highly” endemic settings (Supplementary File 1: Supplementary Table S2).

123 **[Figure 1 here]**

124 **Figure 1. Simple and reversible catalytic model structure and equations fitted to data on the age**  
125 **(a)-specific (sero)prevalence ( $p(a)$ ) data, where  $\lambda$  is the force-of-infection (rate of antibody (Ab)-**  
126 **seroconversion or infection acquisition) and  $\rho$  the rate of Ab-seroreversion or infection loss.** The  
127 general mathematical form of the catalytic models (equations 1a to 1d) fitted to the human  
128 taeniasis (HTT)/human cysticercosis (HCC) Ab, HCC Ag and HTT copro-Ag prevalence datasets to  
129 estimate the prevalence ( $p$ ) at human age ( $a$ ). The saturating (sero)prevalence is given by  $\lambda/(\lambda + \rho)$   
130 which for the simple model is 100%, if the humans lived sufficiently long. The accompanying tables  
131 provide information on the definitions of the catalytic model parameters depending on the  
132 diagnostic method. Presence of adult tapeworm excretory-secretory products indicative of active  
133 or past HTT infection, as outlined by Lightowers et al. 2016a.

134

135 **Global human taeniasis (HTT) copro-antigen and antibody seroprevalence**

136 Table 1 compares models fitted either including (reversible model) or excluding (simple model) HTT  
137 infection loss (when fitted to copro-Ag ELISA using the Allan et al. (1990) protocol datasets, except  
138 in Gomes et al. (2002) where a protocol is not specified) or Ab-seroreversion. For the copro-Ag ELISA  
139 datasets (to which models were jointly fitted to yield a single sensitivity and specificity posterior),  
140 DIC scores were similar (within one unit) between models with and without infection loss (Table 1  
141 and Figure 2a), indicating limited information to differentiate between model fits.

142 The copro-Ag ELISA datasets (Gomes et al., 2002; Mwape et al., 2012) were found in hyperendemic  
143 settings (all-age HTT (sero)prevalence  $\geq 3\%$ ) in Zambia (6.3%) (Mwape et al., 2012) and Brazil (4.5%)  
144 (Gomes et al., 2002). For the models independently fitted to the single dataset in Lao People's  
145 Democratic Republic (Lao PDR) (Holt et al., 2016) using the rES33-immunoblot (Wilkin et al., 1999)  
146 and found in an endemic setting (all-age HTT antibody seroprevalence of 2.5%), there was also  
147 limited information to differentiate between model fits, with DIC scores similar (within one unit)  
148 between the model with and without Ab-seroconversion (Table 1 and Figure 2b). The FoI ( $\lambda_{sero}$ ) for  
149 the best-fit model to the rES33-immunoblot antibody dataset in Lao PDR (Holt et al., 2016),  
150 suggested a very low HTT Ab-seroconversion rate of  $0.00046 \text{ year}^{-1}$  (all model fits and DIC scores  
151 in Supplementary File 1: Supplementary File Table S3). The Madinga et al. (2017) dataset in the  
152 DRC was omitted from the models jointly fitted across copro-Ag ELISA datasets, due to difficulty  
153 fitting catalytic models to such a distinct age-prevalence profile with a marked peak in early ages  
154 (see Discussion).

155 **[Figure 2 here]**

156 **Figure 2. The relationship between human taeniasis copro-antigen (Copro-Ag) and antibody**  
157 **(sero)prevalence and human age (in years) for each dataset.** Human taeniasis (HTT) infection  
158 acquisition (simple) or acquisition with infection loss (reversible) catalytic models jointly fitted to  
159 multiple datasets (where single diagnostic sensitivity and specificity values were estimated; dataset-  
160 specific  $\lambda$  and  $\rho$  estimates were obtained) in **a**); HTT antibody (Ab)-seroconversion (simple) or Ab-  
161 seroconversion with Ab-seroreversion to a single dataset in **b**). 95% confidence intervals associated  
162 with observed (sero)prevalence point estimates are also presented. Bayesian Markov chain Monte  
163 Carlo methods were used to fit the models to data, with the parameter posterior distributions used  
164 to construct predicted (all age) (sero)prevalence curves and associated 95% Bayesian credible  
165 intervals (BCIs). Best-fitting model selected by deviance information criterion (DIC); both models  
166 presented if difference between  $\text{DIC} < 2$  (both models have similar support based on the data); a

167 difference > 10 units indicates that the models are significantly different and therefore only superior  
 168 fitting model (lowest DIC) is presented). The non-zero predicted (sero)prevalence at age 0 is due to  
 169 less than 100% specificity for all tests. The 95% confidence intervals (95% CI) for age-(sero)prevalence  
 170 data-points are calculated by the Clopper-Pearson exact method.

**Table 1.** (Sero)prevalence and parameter posterior estimates for the best-fit catalytic models fitted to human taeniasis (antibody and antigen) age-(sero)prevalence datasets (ordered by decreasing all-age (sero)prevalence).

Dataset	All-age observed (sero)-prevalence (%) (95% CI)*	Catalytic model	Diagnostic sensitivity (95% BCI)	Diagnostic specificity (95% BCI)	$\lambda$ = infection acquisition ( $\lambda_{inf}$ ) or Ab-seroconversion ( $\lambda_{sero}$ ) rate, year <sup>-1</sup> (95% BCI)**	$\rho$ = infection loss ( $\rho_{inf}$ ) or Ab-seroreversion ( $\rho_{sero}$ ) rate, year <sup>-1</sup> (95% BCI)**
Models jointly fitted to multiple datasets (Copro-Ag ELISA) <sup>a</sup>						
Mwape et al. 2012 Antigen <sup>†</sup>	6.32 (4.65 – 8.37)	Reversible <sup>b</sup>	0.824 (0.533 – 0.972)	0.959 (0.941 – 0.976)	0.021 (0.0038 – 0.062)	0.768 (0.362 – 0.991)
Gomes et al. 2002 Antigen <sup>††</sup>	4.51 (2.97 – 6.54)				0.0096 (0.00072 – 0.032)	0.731 (0.379 – 0.978)
Models independently fitted to single datasets (rES33-immunoblot) <sup>c</sup>						
Holt et al. 2016 Antibody	2.49 (1.51 – 3.87)	Simple <sup>d</sup>	0.982 (0.959 – 0.996)	0.992 (0.978 – 0.999)	0.00044 (0.000103 – 0.00082)	NA

\*Observed (sero)prevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.

\*\*Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI).



---

† Based on the Allan et al. (1990) protocol.

†† no protocol specified (assumed to be the Allan et al. (1990) protocol).

NA = Not applicable.

<sup>a</sup>Diagnostic sensitivity and specificity jointly fitted for the Copro-Ag ELISA (Allan et al., 1990) across age-prevalence datasets; model parameters interpreted in terms of representing infection, with infection acquisition ( $\lambda_{inf}$ ) and infection loss ( $\rho_{inf}$ ) rates.

<sup>b</sup>Best-fitting model determined by DIC (models jointly fitted to multiple dataset).

<sup>c</sup>Model parameters for antibody-based age-seroprevalence data (based on the rES33-immunoblot (Wilkins et al., 1999)), interpreted in terms of exposure, with Ab-seroconversion ( $\lambda_{sero}$ ) and Ab-seroreversion ( $\rho_{sero}$ ) rates.

<sup>d</sup>Best-fitting model determined by DIC (models independently fitted to single dataset).

171

172

### 173 **Global human cysticercosis (HCC) antibody seroprevalence**

174 HCC Ab-seroconversion with Ab-seroreversion (reversible model) provided an improved joint fit to  
175 the multiple datasets based on the antibody lentil lectin-purified glycoprotein enzyme-linked  
176 immunoelectrotransfer blot (LLGP-EITB) assay (Tsang et al., 1989) (Table 2 and Figure 3a). These  
177 fits were found in the proposed hyperendemic settings ( $\geq 6\%$  HCC seroprevalence; with all-age  
178 seroprevalence from 12.7% to 24.7%) in Peru (Lescano et al., 2009; Moro et al., 2003), India  
179 (Jayaraman et al., 2011), and Bali (Theis et al., 1994), and an endemic setting in Brazil (1.6%)  
180 (Gomes et al., 2002). For the models jointly fitted to multiple datasets based on the IgG Ab-ELISA  
181 (*DiagAutom*, 2016) hyperendemic setting: all-age seroprevalence from 9.6% to 14.5%) in Nigeria  
182 (Edia-Asuke et al., 2015; Weka et al., 2013), and the models independently fitted to the single  
183 dataset from Lao PDR (endemic setting: 3.0% all-age seroprevalence) (Holt et al., 2016) based on  
184 the rT24H-immunoblot (Hancock et al., 2006), the (simple) model without Ab-seroreversion  
185 provided an improved fit (Table 2 and Figure 3b and 3c). Supplementary File 1: Supplementary File  
186 Table S4 presents all model fits and DIC scores.

187 **[Figure 3 here]**

188 **Figure 3. The relationship between human cysticercosis antibody (Ab)-seroprevalence and human**  
189 **age (in years) for each dataset.** Ab-seroconversion (simple) or Ab-seroconversion with Ab-  
190 seroreversion (reversible) catalytic models (a & b) jointly fitted to multiple datasets (single diagnostic  
191 sensitivity and specificity values estimated; dataset-specific  $\lambda_{sero}$  and  $\rho_{sero}$  estimates obtained) and (c)  
192 models independently fitted to a single dataset, including 95% confidence intervals associated with  
193 observed Ab-seroprevalence point estimates. Bayesian Markov chain Monte Carlo methods were used  
194 to fit the models to data, with the estimated parameter posterior distributions used to construct  
195 predicted (all age) seroprevalence curves and associated 95% Bayesian credible intervals (BCIs). Best-  
196 fitting models were selected using the deviance information criterion (DIC); both models presented if  
197 difference between DIC < 2 (both models have similar support based on the data); a difference > 10  
198 units indicates that the models are significantly different and therefore only superior fitting model  
199 (lowest DIC) is presented). The non-zero predicted seroprevalence at age 0 is due to less than 100%  
200 specificity for all tests. The 95% confidence intervals (95% CIs) for age-seroprevalence data-points are  
201 calculated by the Clopper-Pearson exact method.

202

**Table 2.** Antibody seroprevalence and parameter estimates for the best-fit catalytic models fitted to each observed human cysticercosis (antibody) age-seroprevalence dataset (ordered by decreasing all-age seroprevalence).

Dataset	All-age observed seroprevalence (%) (95% CI)*	Catalytic model	Diagnostic sensitivity (95% BCI)	Diagnostic specificity (95% BCI)	$\lambda_{sero}$ = seroconversion rate, year <sup>-1</sup> (95% BCI)**	$\rho_{sero}$ = seroreversion rate, year <sup>-1</sup> (95% BCI)**
Models jointly fitted to multiple datasets (LLGP-EITB assay) <sup>a</sup>						
Lescano et al. 2009	24.66 (21.59 – 27.94)	Reversible <sup>b</sup>	0.976 (0.937 – 0.994)	0.980 (0.967 – 0.988)	0.12 (0.067 – 0.19)	0.38 (0.21 – 0.62)
Moro et al. 2003	20.82 (16.48 – 25.71)				0.11 (0.0504 – 0.21)	0.501 (0.23 – 0.92)
Jayaraman et al. 2011	15.81 (13.66 – 18.16)				0.019 (0.0095 – 0.093)	0.105 (0.042 – 0.56)
Theis et al. 1994	12.68 (10.48 – 15.16)				0.024 (0.011 – 0.052)	0.16 (0.054 – 0.38)
Gomes et al. 2002	1.64 (0.82 – 2.93)				0.000086 (0.000011 – 0.00066)	0.43 (0.098 – 1.49)
Models jointly fitted to multiple datasets (IgG Ab-ELISA) <sup>c</sup>						
Edia-Asuke et al. 2015	14.53 (10.72 – 19.06)	Simple <sup>b</sup>	0.872 (0.784 – 0.942)	0.974 (0.916 – 0.998)	0.0044 (0.0018 – 0.0064)	NA

Weka et al. 2013	9.60 (5.06 – 16.17)				0.0023 (0.00053 – 0.0046)	NA
Models independently fitted to an single dataset (rT24H-immunoblot) <sup>d</sup>						
Holt et al. 2016	2.96 (1.86 – 4.44)	Simple <sup>e</sup>	0.964 (0.914 – 0.988)	0.986 (0.969 – 0.997)	0.00044 (0.000049 – 0.00090)	NA

\*Observed seroprevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.

\*\*Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI).

NA = Not applicable.

<sup>a</sup>Diagnostic sensitivity and specificity jointly fitted for the LLGP-EITB assay (Tsang et al., 1989) across datasets.

<sup>b</sup>Best-fitting model determined by DIC (models jointly fitted to multiple datasets).

<sup>c</sup>Diagnostic sensitivity and specificity jointly fitted for the IgG Ab-ELISA (DiagnosticAutomation/CortezDiagnostic, Inc., 2016) across datasets.

<sup>e</sup>Based on the rT24H-immunoblot (Hancock et al., 2006).

<sup>d</sup>Best-fitting model determined by DIC (models independently fitted to a single dataset).

203

204 **Global human cysticercosis (HCC) antigen seroprevalence**

205 HCC infection acquisition with infection loss (reversible model) provided an improved fit for models  
 206 fitted jointly to multiple datasets based on B158/B60 Ag-ELISA (Brandt et al., 1992; Dorny et al.,  
 207 2000) (Table 3 and Figure 4a), found in one hyperendemic setting (all-age HCC seroprevalence of  
 208 21.7%) in the DRC (Kanobana et al., 2011), and endemic settings in Zambia (Mwape et al., 2012),  
 209 Burkina Faso (Sahlu et al., 2019), Lao PDR (Conlan et al., 2012) and Cameroon (Ngeuekam et al.,  
 210 2003) (all-age HCC seroprevalences from 0.7% to 5.8%). For models fitted to the single dataset  
 211 from a hyperendemic setting in Kenya (6.61%) (Wardrop et al., 2015), using the HP10 Ag-ELISA  
 212 (Harrison et al., 1989), the (simple) model without infection loss provided an improved fit (Table 3

213 and Figure 4b). Supplementary File 1: Supplementary File Table S5 presents all model fits and DIC  
214 scores.

215 **[Figure 4 here]**

216 **Figure 4. The relationship between human cysticercosis antigen (Ag)-seroprevalence and human age**  
217 **(in years) for each dataset.** Infection acquisition (simple) or infection acquisition and loss (reversible)  
218 catalytic models **(a)** jointly fitted to multiple datasets (single diagnostic sensitivity and specificity values  
219 estimated; dataset-specific  $\lambda_{inf}$  and  $\rho_{inf}$  estimates obtained) and **(b)** models independently fitted to a  
220 single dataset, including 95% confidence intervals associated with observed Ag-seroprevalence point  
221 estimates. Bayesian Markov chain Monte Carlo methods were used to fit the models to data, with the  
222 parameter posterior distributions used to construct predicted (all age) seroprevalence curves and  
223 associated 95% Bayesian credible intervals (BCIs). Best-fitting model selected by deviance information  
224 criterion (DIC); both models presented if difference between DIC < 2 (both models have similar support  
225 based on the data); a difference > 10 units indicates that the models are significantly different and  
226 therefore only superior fitting model (lowest DIC) is presented). The non-zero predicted seroprevalence  
227 at age 0 is due to less than 100% specificity for all tests. The 95% confidence intervals (95% CI) for age-  
228 seroprevalence data-points are calculated by the Clopper-Pearson exact method.

229

**Table 3.** Antigen seroprevalence and parameter estimates for the best-fit catalytic models fitted to each observed human cysticercosis (antigen) age-seroprevalence dataset (ordered by decreasing all-age seroprevalence).

Dataset	All-age observed seroprevalence (%) (95% CI)*	Catalytic model	Diagnostic sensitivity (95% BCI)	Diagnostic specificity (95% BCI)	$\lambda_{inf}$ = infection acquisition rate, year <sup>-1</sup> (95% BCI)**	$\rho_{inf}$ = infection loss rate, year <sup>-1</sup> (95% BCI)**
Models jointly fitted to multiple datasets (the B158/B60 Ag-ELISA) <sup>a</sup>						
Kanobana et al. 2011	21.66 (19.01 – 24.49)	Reversible <sup>b</sup>	0.909 (0.810 – 0.967)	0.999 (0.995 – 0.999)	0.11 (0.077 – 0.17)	0.330 (0.246 – 0.464)
Mwape et al. 2012	5.79 (4.19 – 7.77)				0.0044 (0.0027 – 0.0088)	0.023 (0.001 – 0.085)
Sahlu et al. 2019	2.45 (1.93 – 3.08)				0.0016 (0.00091 – 0.0032)	0.029 (0.0016 – 0.11)
Conlan et al. 2012	2.22 (1.49 – 3.17)				0.0018 (0.00073 – 0.0034)	0.063 (0.0076 – 0.12)
Nguekam et al. 2003	0.68 (0.47 – 0.95)				0.00017 (0.000077 – 0.00030)	0.004 (0.00018 – 0.026)
Models independently fitted to a single dataset (the HP10 Ag-ELISA) <sup>c</sup>						
Wardrop et al. 2015	6.61 (5.57 – 7.76)	Simple <sup>d</sup>	0.850 (0.735 – 0.927)	0.944 (0.930 – 0.959)	0.00054 (0.000053 – 0.0013)	NA

\*Observed seroprevalence data are accompanied by 95% confidence intervals (95% CI) calculated by the Clopper-Pearson exact method.

---

\*\*Parameter median posterior estimates are presented with 95% Bayesian credible intervals (95% BCI).

NA = Not applicable.

<sup>a</sup>Diagnostic sensitivity and specificity jointly fitted for the B158/B60 Ag-ELISA (Brandt et al., 1992; Dorny et al., 2000).

<sup>b</sup>Best-fitting model determined by DIC (models jointly fitted to multiple datasets).

<sup>c</sup>Based on the HP10 Ag-ELISA (Harrison et al., 1989).

<sup>d</sup>Best-fitting model determined by DIC (models independently fitted to a single dataset).

230

231

## 232 **Country-wide analysis of human cysticercosis antibody seroprevalence trends in Colombia**

233 HCC Ab-seroconversion with Ab-seroreversion (reversible model), fitted to multiple datasets using  
234 an IgG Ab-ELISA (López et al. 1988), provided an improved fit across the 23 (out of a total of 24)  
235 departments of Colombia (Flórez Sánchez et al., 2013) included in the analysis. Supplementary File  
236 1: Supplementary Table S6 presents parameter estimates from the best-fit reversible model by  
237 department (parameter estimates for the simple model fits by department can also be found in  
238 Supplementary Table S7). Figure 5 presents the best-fit Ab-seroconversion with Ab-seroreversion  
239 (reversible) model fit to each age-seroprevalence dataset across departments (Supplementary File  
240 1: Supplementary Figure S3 zooms into model fits in medium to lower all-age seroprevalence  
241 departments for improved resolution). One department (Bolívar) was omitted due to difficulty  
242 fitting to such a distinct age-seroprevalence profile (prevalence peak in early ages).

243 Figure 6 highlights the geographical variation in a) HCC Ab-seroconversion or FoI, b) HCC Ab-  
244 seroreversion rate and c) the HCC antibody all-age seroprevalence, across the 23 departments. In  
245 addition, Figure 6 presents substantial geographical variation in risk factors, including: d) the  
246 proportion of individuals owning pigs, and e) the proportion of individuals reporting open  
247 defecation practices by department (Supplementary File 1: Supplementary Figure S4 highlights  
248 variation in the proportion of pigs being kept under free-ranging management practices and the  
249 proportion of pigs being kept under free-ranging/mixed practices in those owning pigs ( $n=3,157$ )).

250 **[Figure 5 here]**

251 **Figure 5. The relationship between human cysticercosis antibody (Ab)-seroprevalence and human**  
252 **age (in years) for 23 departments in Colombia.** Each graph shows observed human cysticercosis Ab  
253 age-seroprevalence data (black points) and fitted reversible model (Ab-seroconversion with Ab-  
254 seroreversion; best-fitting model). Y-axis units are from 0-1 (HCC Ab-seroprevalence), with major y-  
255 axis gridlines at 0, 0.2, 0.4, and 0.6 seroprevalence. X-axis units are from 0-80 years (human age), with  
256 major x-axis gridlines at 0, 20, 40, 60 and 80 years of age. *Note: Supplementary File 1: Supplementary*  
257 *Figure S7 zooms into predicted plots for a) medium all-age HCC Ab-seroprevalence (6.33–14.37% all-*  
258 *age seroprevalence) and b) low all-age HCC Ab-seroprevalence (0.48–4.92% all-age seroprevalence),*  
259 *to view more closely the age-seroprevalence trends and uncertainty around fitted seroprevalence.*

260 **[Figure 6 here]**

261 **Figure 6.** Geographic variation in, a) HCC antibody (Ab)-seroconversion rate ( $\lambda_{\text{sero}}$  or Fol), and b) HCC  
262 Ab-seroreversion rate ( $\rho_{\text{sero}}$ ), c) human cysticercosis Ab all-age seroprevalence data, d) pig ownership  
263 proportion and e) open defecation reported proportion by department. The Fol ( $\lambda_{\text{sero}}$ ) and Ab-  
264 seroreversion ( $\rho_{\text{sero}}$ ) rates are parameter estimates obtained from the best-fit model with HCC Ab-  
265 seroconversion and Ab-seroreversion (reversible model). Note that San Andrés department is not  
266 clearly shown because of its size (small islands located in the top-left of a-c maps). For context, an  
267 all-age HCC Ab-seroprevalence = 0.126, HCC Ab-seroconversion rate (Fol or  $\lambda_{\text{sero}}$ ) = 0.023 year<sup>-1</sup>, and  
268 HCC Ab-seroreversion rate ( $\rho_{\text{sero}}$ ) = 0.19 year<sup>-1</sup> was obtained in San Andrés

269

270 **Force-of-infection across settings**

271 A more intuitive approach to understanding the Fol ( $\lambda$ ) is to consider its reciprocal, which here  
272 corresponds to the average time until humans become Ab-seropositive ( $1/\lambda_{\text{sero}}$ ) or infected ( $1/\lambda_{\text{inf}}$ )  
273 as inferred through Ag-seropositivity. Equally, the reciprocal of  $\rho$  relates to the average duration  
274 that humans remain Ab-seropositive ( $1/\rho_{\text{sero}}$ ) or infected ( $1/\rho_{\text{inf}}$ ). Given the large number of



275 estimates obtained for HCC, parameter estimates from best-fit models were compared across  
276 settings (by all-age (sero)prevalence of each dataset and by country). Figure 7 shows an overall  
277 decline in the average time (in years) until humans become HCC Ab-seropositive or infected with  
278 increasing all-age HCC (sero)prevalence, noting 18 studies identified in endemic settings (0.48–  
279 5.71% all-age HCC (sero)prevalence), and 19 estimates in hyperendemic settings (6.33–38.68% all-  
280 age HCC seroprevalence). Within countries, there was significant variation in times until humans  
281 become HCC Ab-seropositive or infected (Supplementary File 1: Supplementary Figure S5a).

282 Figure 7b presents strong evidence for similar average durations of remaining Ab-seropositive  
283 ( $1/\rho_{sero}$ ) across different endemicity settings and countries (Supplementary File 1: Supplementary  
284 Figure S5b). However, there was evidence for a trend of decreasing duration of humans remaining  
285 infected ( $1/\rho_{inf}$ ) with increasing all-age prevalence (antigen-based studies; n=5).

286 **[Figure 7 here]**

287 **Figure 7. The relationship between (a) the average time until humans become cysticercosis**  
288 **antibody (Ab)-seropositive or infected ( $1/\lambda$ ) and overall (all-age) seroprevalence, and (b) the**  
289 **average time humans remain cysticercosis Ab seropositive or infected ( $1/\rho$ ) and overall (all-age)**  
290 **seroprevalence.** The plot is stratified by proposed endemicity levels defined as endemic (>0% and  
291 <6% all-age HCC seroprevalence), and hyperendemic ( $\geq 6\%$  all-age HCC seroprevalence).

292

## 293 **Discussion**

294 This paper presents the first global FoI estimates for *T. solium* HTT and HCC, identifying geographical  
295 heterogeneity that supports calls to implement both locally-adapted control efforts (Johansen et  
296 al., 2017; Gabriël et al., 2017), and setting-specific parameterisations of *T. solium* transmission  
297 models to support such efforts (Dixon et al., 2019). We have also placed our HTT FoI estimates in  
298 the context of (putative) endemic or hyperendemic settings, with 0.44 per 1,000 people per year

299 for a (single) endemic setting, and from 9.6 to 21 per 1,000 per year for 2 hyperendemic settings.  
300 HCC FoI estimates ranged from 0.086 to 21 per 1,000 per year in (18, including Colombian  
301 departments) endemic settings (0.086–21 for Ab-based surveys; 0.17–4.4 for Ag-based surveys),  
302 and from 0.54–120 per 1,000 per year in (19) hyperendemic settings (2.3–120 for Ab-based surveys;  
303 0.54–110 for Ag-based surveys). Further work will be required to refine the proposed (and  
304 preliminary) characterisation of endemicity levels, perhaps linked to severity/morbidity (as in other  
305 NTDs (Prost et al., 1979; Smith et al., 2013). This will be relevant to inform what constitutes a  
306 hyperendemic setting in need of intensified control interventions, as proposed in the WHO 2021–  
307 2030 goals for *T. solium* (World Health Organization, 2020). Our work also follows the 5 principles  
308 distilled by Behrend et al. (2020) for communicating policy-relevant NTD modelling to stakeholders  
309 and implementation partners (Supplementary File 1: Supplementary File Table S8).

310 Across epidemiological settings, there was a clear trend of decreasing average time until humans  
311 become HCC Ab-seropositive or infected as inferred through Ag-seropositivity (the reciprocal of  $\lambda_{sero}$   
312 or  $\lambda_{inf}$ ) with increasing all-age seroprevalence. This makes intuitive sense as the FoI increases in  
313 settings with more intense transmission (reflected by a higher all-age seroprevalence). It was not  
314 possible to discern whether such trends exist for HTT given the limited availability of HTT datasets  
315 with age-stratified prevalence data. Infection loss with infection acquisition was indicated for two  
316 HTT copro-Ag-ELISA-based surveys, and five of six HCC antigen-based surveys, supporting inclusion  
317 of parameters representing recovery from HTT and HCC in *T. solium* transmission models (Dixon et  
318 al., 2019). Our infection loss rates for HTT indicate that the duration of adult tapeworm infection  
319 (the reciprocal of  $\rho_{inf}$ ) ranges from 1.3 to 1.4 years (with uncertainty bounds from 1.0 to 2.8 years),  
320 aligning with literature estimates suggesting that adult tapeworms live for less than 5 years (Garcia  
321 et al., 2014), although our values are only based on two studies. HCC Ab-seroreversion rates (or  
322 infection loss rates) from this analysis are also consistently larger than HCC Ab-seroconversion rates  
323 (or infection acquisition rates), in agreement with comparisons of HCC Ab-seroreversion to Ab-  
324 seroconversion (or Ag-seroreversion to Ag-seroconversion) estimates in the literature, which are

325 generally based on cumulative seroconversion and seroreversion proportions, or rule-based  
326 modelling approaches (Dermauw et al., 2018; Garcia et al., 2001; Coral-Almeida et al., 2015; Mwape  
327 et al., 2013).

328 Some of the modelled estimates presented here indicate large differences between FoI and Ab-  
329 seroreversion/infection loss rates. These differences are particularly evident in datasets, such as  
330 Brazil (Gomes et al., 2002) and Risaralda Department in Colombia (Flórez Sánchez et al., 2013),  
331 where the reversible model was selected for flat age-(sero)prevalence profiles in low  
332 (sero)prevalence settings, where the seroreversion parameter provided minimal information with  
333 large uncertainty. The flat age-(sero)prevalence in these settings may also be likely explained by  
334 false-positives generated given the slightly sub-optimal performance of the serological antibody  
335 diagnostic used (e.g. posterior median specificity estimates of 98% in Brazil (Gomes et al., 2002) for  
336 the antibody LLGP-EITB test (Tsang et al., 1989), highlighting issues with imperfect specificity of  
337 diagnostics in settings with very low transmission intensity.

338 The high cysticercosis Ab-seroreversion rates indicated across datasets are likely indicative of  
339 substantial transient responses generated from exposure without establishment of infection. This  
340 may also explain the high all-age Ab-seroprevalence estimates observed in field studies (Garcia et  
341 al., 2001). Even with Ag-based surveys, a marker of infection rather than exposure, Ag-positivity  
342 may still indicate some degree of transient responses due to partial establishment of (immature)  
343 cysts or establishment followed by rapid degeneration of (mature) cysts (Mwape et al., 2012). One  
344 expectation was that Ab-seroreversion and infection loss rates are fundamentally biological  
345 processes so would be fairly consistent across settings. Since Ab-seroreversion or infection loss  
346 parameters were allowed to vary among settings, the consistency of the posterior estimates for  
347 these parameters indicates that rates of HCC Ab-seroreversion are stable (i.e., no relationship  
348 between all-age Ab-seroprevalence and the average duration humans remain Ab-seropositive,  
349 Figure 7b; no relationship between the Ab-seroconversion and Ab-seroreversion rates,

350 Supplementary Figure S6), confirming this *a priori* expectation. The average duration humans  
351 remain infected (i.e., the reciprocal of the HCC infection loss rate), however, decreases with  
352 increasing seroprevalence (and a positive relationship between infection acquisition rates and  
353 infection loss rates, Supplementary Figure S6). Such a signal seen for Ag-based estimates, albeit  
354 with only 5 observations, may indicate increased transient responses in higher transmission settings  
355 due to more partial establishment of infection. There is however an absence of wider literature to  
356 support the hypothesis of exposure intensity affecting probability of successful parasite  
357 establishment, but such (transmission intensity-dependent) parasite establishment processes have  
358 been incorporated into transmission models for other NTDs (Hamley et al., 2019), highlighting an  
359 area of future research with implications for control efforts. In the case of Ab-seroreversion rates,  
360 where more data are available compared to infection loss rates, it may be suitable in future work  
361 to jointly fit the  $\rho_{sero}$  parameter for reversible models across settings.

362 This analysis also provides, for the first time, a detailed country-level analysis, focused on Colombia,  
363 exploring the geographical variation of key epidemiological metrics (Fol and antibody  
364 seroreversion) alongside understanding potential drivers of these trends, using a rich dataset  
365 generated by Flórez Sánchez and colleagues (2013). Our results identify substantial subnational  
366 variation in HCC Fol (measured by Ab-seroconversion) and Ab-seroreversion rates. There appears  
367 to be only a limited relationship between these epidemiological quantities, Ab-seroprevalence and  
368 other risk factors, including open defecation and pig ownership at the department level,  
369 highlighting the complex nature of exposure drivers for HCC. For example, the southeastern rural  
370 departments of Vaupés and Amazonas show the highest all-age seroprevalence and Fol estimates.  
371 But while Vaupés has one of the highest reported proportions of open defecation, pig ownership is  
372 low in both departments. Notwithstanding, substantial subnational variation indicates the need for  
373 tailored subnational approaches to control. Spatial variation has been explored formally for this  
374 dataset by including spatial structure (i.e., spatial correlation in seropositivity estimated up to  
375 approximately 140 km at the Municipality level) into a risk factor analysis, and identifying hot spots

376 of unexplained residual clustering in northern and southern municipalities in Colombia (Galipó et  
377 al., 2021). The findings from this study further supports the requirement for designing subnational  
378 and targeted interventions (risk groups such as those with low education levels and displaced  
379 persons), alongside the need to understand epidemiological dynamics at the subnational level.

380 A potential limitation of this study is the assumption that diagnostic sensitivity and specificity for a  
381 single diagnostic test do not vary substantially among settings (implied by estimating a single  
382 posterior for specificity and sensitivity using data from multiple surveys that used the same  
383 diagnostic). In reality, there may be some variation in diagnostic performance between settings,  
384 particularly for HTT serological diagnostics. For example, the widely used copro-Ag ELISA for  
385 detecting adult tapeworm infection is not species specific (Ng-Nguyen et al., 2017). Literature  
386 estimates indicate high specificity of HCC diagnostics; however, a proportion of positive results by  
387 both HCC Ag- and Ab- diagnostics may be due to transient responses and cross-reactions following  
388 exposure to the eggs of other other helminths including *Taenia saginata*, *Echinococcus granulosus*  
389 and *Schistosomia species* (Lightowlers et al., 2016b; Noh et al., 2014; Kojic et al., 2003; Furrows et  
390 al., 2006). Limited information exists on the co-distribution and prevalence of potentially cross-  
391 reactive *Taenia* species (such as *Taenia saginata*) and other helminths to determine the relative  
392 contribution of within- and between-location variability in the performance of specific diagnostic  
393 tests.

394 The prevailing (and most parsimonious) assumption governing the behaviour of the catalytic  
395 models fitted in this analysis is of a constant FoI with respect to age. Collated age-(sero)prevalence  
396 profiles presented here largely reveal increasing (sero)prevalence with age, or saturation with age  
397 through Ab-seroreversion/infection loss, but this behaviour can also be observed with age-  
398 dependent infection rates (Grenfell and Anderson, 1985). However, the available data limit the  
399 testing of more complex FoI functions. A few datasets appeared indeed to deviate from the basic  
400 assumption, for example for HTT dynamics in the DRC (Madinga et al., 2017) and Bolívar in Colombia

401 (Flórez Sánchez et al., 2013). While it was not possible to fit the current formulation of catalytic  
402 models to these datasets, the specific age-prevalence peaks in younger ages may indicate other  
403 drivers such as heterogeneity in exposure (by age) or age-related immunity mechanisms. The  
404 observations of HTT copro-Ag-ELISA age-prevalence peaks/odds of infection in children from Peru,  
405 Guatemala and Zambia (Garcia et al., 2003a; Allan et al., 1996; Mwape et al., 2015) suggest that  
406 these trends might be more widespread. Age peaks in HTT prevalence could indicate the need for  
407 targeted mass drug administration (MDA) programmes, such as delivery of anthelmintics  
408 (praziquantel) to school-age children, an approach that could be integrated into existing  
409 schistosomiasis control programmes where HTT and schistosomiasis are co-endemic. Should more  
410 age-prevalence data become available, especially for HTT, fitting models with age-varying FoI may  
411 become relevant as indicated in other NTDs (Gambhir et al., 2009).

412 The results presented here, particularly for HCC, where many datasets were available, suggest  
413 marked geographical heterogeneity in FoI and associated all-age (sero)prevalence estimates. This  
414 indicates substantial variation in the intensity of *T. solium* transmission among endemic settings.  
415 There is strong evidence for both HCC Ab-seroreversion and infection loss, likely due to transient  
416 dynamics which highlights the need for careful interpretation of cross-sectional (sero)prevalence  
417 survey estimates. Catalytic models provide useful tools for interpreting such data, which are far  
418 more abundant than a few longitudinal surveys reported in the literature. We also quantify, for the  
419 first time, the presence of substantial subnational variation in exposure to HCC, highlighting the  
420 need for tailored, sub-national control strategies. More work is also required to understand  
421 whether age-prevalence peaks (as observed for HTT) are more commonplace, and whether age-  
422 targeted control strategies may be required under specific epidemiological and socioeconomic  
423 conditions.

424

## 425 **Materials and methods**

### 426 **Identifying relevant literature, data sources and data extraction**

427 Published articles with HTT and HCC age-(sero)prevalence *or* age-infection data suitable for  
428 constructing age-stratified profiles were identified through two routes. Firstly, by extracting  
429 eligible studies from a systematic review of *T. solium* HTT and HCC (sero)prevalence global ranges  
430 (Coral-Almeida et al. (2015)), and secondly, by updating the Coral-Almeida et al. (2015) review,  
431 using the same strategy (see Supplementary File 1: Supplementary Text S1), for the period  
432 01/11/2014 to 02/10/2019.

### 433 **Sub-national dataset for Colombia**

434 Flórez Sánchez et al. (2013) conducted a country-level survey of HCC antibody seroprevalence  
435 across 24 of Colombia's 32 administrative departments, sampling 29,360 individuals. Permission  
436 was granted from *Instituto Nacional de Salud* to analyse these data to construct age-  
437 seroprevalence profiles. The study collected human cysticercosis Ab-seroprevalence data in the  
438 period 2008–2010, alongside risk-factor data using a three-stage clustered random sampling  
439 framework. To maintain suitable sample sizes for model fitting, age-seroprevalence profiles were  
440 constructed at the department level ( $n = 850$ – $1,291$ ; Supplementary File 1: Supplementary Figure  
441 S7), rather than at municipality level ( $n = 40$ – $1,140$ ). Age-seroprevalence profiles stratified by sex  
442 in each department revealed no clear differences (Supplementary File 1: Supplementary Figure  
443 S8a), therefore age-seroprevalence data were not stratified by sex for further analysis (but see  
444 Galipó et al., 2021). Due to difficulty fitting the specific catalytic models to data from the  
445 department of Bolívar, only 23 of 24 departments were assessed ( $n = 28,100$ ).

### 446 **Force-of-infection modelling for human taeniasis and human cysticercosis**

447 The FoI, which describes the average (per capita) rate at which susceptible individuals seroconvert  
448 (become Ab-positive) or become infected, was estimated for HTT and HCC for each dataset. Simple

449 and reversible catalytic models (Figure 1), originally proposed for fitting to epidemiological data by  
450 Muench (1934), were fitted to HTT and HCC age-(sero)prevalence profiles. Model parameters fitted  
451 to Ab-datasets were interpreted as Ab-seroconversion ( $\lambda_{sero}$ ) and Ab-seroreversion ( $\rho_{sero}$ ) rates,  
452 while (copro-) Ag-datasets were interpreted as infection acquisition ( $\lambda_{inf}$ ) and infection loss ( $\rho_{inf}$ )  
453 rates (Figure 1 provides further details of model structure and parameter interpretation). Like the  
454 Fol, the infection loss/ seroreversion parameter ( $\rho$ ) was also permitted to vary across settings  
455 (Dermauw et al., 2018).

456 The true prevalence  $p(a)$  at age  $a$  is given for the simple model by,

$$457 \quad p(a) = 1 - e^{-\lambda(a)} \quad [1]$$

458 and for the reversible model by,

$$459 \quad p(a) = \frac{\lambda}{\lambda + \rho} [1 - e^{-(\lambda + \rho)(a)}] \quad [2]$$

#### 460 **Model fitting and comparison**

461 Analyses were performed in R version 4.0.5 (2021), following Dixon et al. (2020). A likelihood was  
462 constructed assuming that the observed data (representing a binary presence/absence of markers  
463 related to exposure or infection) are a realization of an underlying binomial distribution with  
464 probability  $p(a)$ , given by the catalytic model, and adjusted to give the observed prevalence,  $p'(a)$ ,  
465 by the sensitivity ( $se$ ) and specificity ( $sp$ ) of the diagnostic adopted in the respective datasets  
466 (Diggle, 2011),

$$467 \quad p'(a) = 1 - sp + se + sp - 1 \times p(a) \quad [3]$$

468 Therefore, the likelihood of the data on the number of observed Ab-seropositive or infected humans  
469 of age  $a$ ,  $r(a)$ , from  $n(a)$  humans is,

$$470 \quad L(r, n | \theta) = \prod_a p'(a)^{r(a)} [1 - p'(a)]^{n(a) - r(a)} \quad [4]$$



471 where  $\theta$  denotes, generically, the catalytic model (i.e. FoI, seroreversion/infection loss) and  
472 diagnostic performance (i.e., sensitivity and specificity) parameters. When the same diagnostic was  
473 used across surveys, sensitivity and specificity were assumed to be the same among surveys,  
474 yielding a single posterior distribution for the diagnostic performance (sensitivity, specificity) for  
475 each test (whilst retaining dataset-specific estimates of  $\lambda$  and  $\rho$ ). The approach captures  
476 uncertainty in diagnostic sensitivity and specificity, but does not permit variation in performance  
477 across settings.

478 A Bayesian Markov chain Monte Carlo (MCMC) Metropolis–Hastings sampling algorithm was  
479 implemented to estimate the parameter posterior distribution  $f(\theta|r, n)$ , assuming uniform prior  
480 distributions for  $\lambda$  and  $\rho$  (Table 4). A weakly informative prior for  $\lambda$ , assuming a lognormal  
481 distribution (mean informed by the median estimate from the simple model fit, and a standard  
482 deviation of 1), was used for reversible model fits to prevent  $\lambda$  chains drifting to flat posterior space  
483 and failing to converge.

484 Informative beta distribution priors for the diagnostic sensitivity and specificity were defined to  
485 capture literature estimates of the mean and 95% CIs for these parameters; Supplementary File 1:  
486 Supplementary Table S1, Supplementary Figure S9 and S10 provide more detail).

487 A maximum of 20,000,000 iterations were run for models fitted simultaneously to multiple datasets  
488 (2,000,000 for models fitted to single datasets) to obtain a sufficient sample to reduce autocorrelation  
489 through substantial subsampling, with the first 25% of runs being discarded as burn-in. The parameter  
490 posterior distributions, used to generate fitted prevalence curves and associated uncertainties for  
491 each model fit, were summarised using the median and 95% Bayesian credible intervals (95% BCIs).  
492 Simple and reversible model fits were compared using the deviance information criterion (DIC)  
493 (Spiegelhalter et al., 2002), with the model producing the smallest DIC score being selected.

494

**Table 4. Range for force-of-infection (Foi),  $\lambda$ , and seroreversion / infection loss,  $\rho$ , uniform priors.**

<i>T. solium</i> indicator	$\lambda$ : limits on uniform prior (year <sup>-1</sup> )	$\rho$ : limits on uniform prior (year <sup>-1</sup> )	Rationale
HTT (copro-antigen (Ag) and antibody (Ab))	Minimum: 0 Maximum: 12	Minimum: 0.333 Maximum: 1	<p><math>\lambda</math>: maximum seroconversion rate of 12 year<sup>-1</sup> = 1 month<sup>-1</sup> (1/<math>\lambda</math>), representing the lower limit before humans become copro-Ag positive (i.e., infected) or Ab-seropositive of 1 month</p> <p><math>\rho</math>: minimum Ab-seroreversion or infection loss rate of 0.333 year<sup>-1</sup> = 0.0277 month<sup>-1</sup>, or 36-month duration (1/<math>\rho</math>) for humans to remain copro-Ag (i.e., infected) or Ab- seropositive, reflecting the upper average limit assumed for the life- expectancy of adult <i>Taenia solium</i> of 3 years (Gonzalez et al., 2002); a maximum of 0.0833 month<sup>-1</sup> represents the minimum time humans remain copro-Ag (i.e., infected) or Ab-seropositive reflecting the minimum life-expectancy of the adult worm of 12 months (Garcia et al., 2003b) (1/ <math>\rho</math>)</p>
HCC (antigen and antibody)	Minimum: 0 Maximum: 12	Minimum: 0 Maximum: 12	Both $\lambda$ and $\rho$ : maximum infection acquisition/loss or Ab-seroconversion / Ab-seroreversion rate of 12 year <sup>-1</sup> = 1 month <sup>-1</sup> represents the lower limit before humans acquire infection or become Ab-seropositive (1/ $\lambda$ ), or remain HCC antigen (i.e., infected) or Ab-seropositivity (1/ $\rho$ ) of 1 month.
<p><i>N.B.</i> The reciprocal of the rates of <math>\lambda</math> and <math>\rho</math> give the duration of susceptibility (1/<math>\lambda</math>; 1/<math>\lambda_{sero}</math> for Ab-based, or 1/<math>\lambda_{inf}</math> for Ag-based) or of remaining infected or Ab-seropositive (1/<math>\rho</math>; 1/<math>\rho_{sero}</math> for Ab-based, or 1/<math>\rho_{inf}</math> for Ag-based). HTT: human taeniasis; Ab: antibody; Ag: antigen; HCC: human cysticercosis</p>			

495

496

497

498 **Acknowledgements:** NA

499

500 **Competing interests:**

501 All authors declare they do not have conflicts of interest.

502

503 **Funding statement:**

504 MAD, PW, CW, ZMC and MGB acknowledge funding from the Medical Research Council (MRC) Centre  
505 for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK MRC and  
506 the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat  
507 agreement and is also part of the European and Developing Countries Clinical Trials Partnership  
508 (EDCTP2) programme supported by the European Union.

509 **Data and code availability:**

510 Code to replicate the analysis is provided at [https://github.com/mrc-ide/human\\_tsol\\_FoI\\_modelling](https://github.com/mrc-ide/human_tsol_FoI_modelling).

511 All age-(sero)prevalence data are available in the following data repository:

512 <http://doi.org/10.14469/hpc/10047>. Original data for two datasets available (under the [Creative](#)

513 [Commons Attribution License; CC BY 4.0](#)) from the International Livestock Research Institute open-

514 access repository (<http://data.ilri.org/portal/dataset/ecozd>) referenced in Holt et al. (2016) and

515 University of Liverpool open-access repository (<http://datacat.liverpool.ac.uk/352/>) referenced in

516 Fèvre et al. (2017).

517 **References**

- 518 Allan JC, Ávila G, Garcia Noval J, Flisser A, Craig PS (1990) **Immunodiagnosis of taeniasis by**  
519 **coproantigen detection** *Parasitology* **101** Pt 3:473–7. doi: 10.1017/s0031182000060686
- 520 Allan JC, Velasquez-Tohom M, Garcia-Noval J, Torres-Alvarez R, Yurrita P, Fletes C, Mata F de, Soto de  
521 Alfaro H, Craig PS (1996) **Epidemiology of intestinal taeniasis in four, rural, Guatemalan communities**  
522 *Annals of Tropical Medicine and Parasitology* **90(2)**:157–65. doi: 10.1080/00034983.1996.11813039
- 523 Behrend MR, Basáñez MG, Hamley JID, Porco TC, Stolk WA, Walker M, de Vlas SJ; NTD Modelling  
524 Consortium (2020) **Modelling for policy: The five principles of the Neglected Tropical Diseases**  
525 **Modelling Consortium** *PLoS Neglected Tropical Disease* **9**;14(4):e0008033. doi:  
526 10.1371/journal.pntd.0008033.
- 527 Braae, U.C., Gabriël, S., Trevisan, C. Thomas LF, Magnussen P, Abela-Ridder B, Ngowi H, Johansen MV  
528 (2019) **Stepwise approach for the control and eventual elimination of *Taenia solium* as a public**  
529 **health problem** *BMC Infectious Diseases* **19**:182. <https://doi.org/10.1186/s12879-019-3812-y>.
- 530 Brandt JR, Geerts S, De Deken R, Kumar V, Ceulemans F, Brijs L, Falla N (1992) **A monoclonal antibody-**  
531 **based ELISA for the detection of circulating excretory-secretory antigens in *Taenia saginata***  
532 **cysticercosis** *International Journal of Parasitology* **22**:471–7. doi: 10.1016/0020-7519(92)90148-e
- 533 Conlan J V, Vongxay K, Khamlome B, Dorny P, Sripa B, Elliot A, Blacksell SD, Fenwick S, Thompson RC  
534 (2012) **A cross-sectional study of *Taenia solium* in a multiple taeniid-endemic region reveals**  
535 **competition may be protective** *American Journal of Tropical Medicine and Hygiene* **87**:281–91. doi:  
536 10.4269/ajtmh.2012.11-0106.
- 537 Coral-Almeida M, Rodríguez-Hidalgo R, Celi-Erazo M, García HH, Rodríguez S, Devleeschauwer B,  
538 Benítez-Ortiz W, Dorny P, Praet N (2014) **Incidence of human *Taenia solium* larval infections in an**  
539 **Ecuadorian endemic area: implications for disease burden assessment and control** *PLoS Neglected*  
540 *Tropical Diseases* **8**: e2887. doi: 10.1371/journal.pntd.0002887

- 541 Coral-Almeida M, Gabriel S, Abatih EN, Praet N, Benitez W, Dorny P (2015) ***Taenia solium* Human**  
542 **Cysticercosis: A Systematic Review of Sero-epidemiological Data from Endemic Zones around the**  
543 **World** *PLoS Neglected Tropical Diseases* **9**:e0003919. doi: 10.1371/journal.pntd.0003919
- 544 CystiTeam Group for Epidemiology and Modelling of *Taenia solium* Taeniasis/Cysticercosis (2019) **The**  
545 **World Health Organization 2030 goals for *Taenia solium*: Insights and perspectives from**  
546 **transmission dynamics modelling: CystiTeam Group for Epidemiology and Modelling of *Taenia***  
547 ***solium* Taeniasis/Cysticercosis** *Gates Open Research* **3**:1546. doi: 10.12688/gatesopenres.13068.2.
- 548 de Coster T, Van Damme I, Baauw J, Gabriël S (2018) **Recent advancements in the control of *Taenia***  
549 ***solium*: A systematic review** *Food and Waterborne Parasitology* **13**:e00030. doi:  
550 10.1016/j.fawpar.2018.e0003.
- 551 Dermauw V, Carabin H, Ganaba R, Cissé A, Tarnagda Z, Gabriël S, Dorny P, Millogo A (2018) **Factors**  
552 **Associated with the 18-Month Cumulative Incidence of Seroconversion of Active Infection with**  
553 ***Taenia solium* Cysticercosis: A Cohort Study among Residents of 60 Villages in Burkina** *American*  
554 *Journal of Tropical Medicine and Hygiene* **99**(4):1018-1027. doi: 10.4269/ajtmh.18-0294.
- 555 DiagAutom. Human Cysticercosis IgG (*T. Solium*) ELISA Test kit. 2016. Available from:  
556 <http://www.rapidtest.com/index.php?i=Parasitology-ELISA-kits&id=170&cat=17> [accessed 2020 Mar  
557 9].
- 558 Diggle P (2011) **Estimating Prevalence Using an Imperfect Test** *Epidemiology Research International*.  
559 doi: 10.1155/2011/608719
- 560 Dixon MA, Braae UC, Winskill P, Walker M, Devleeschauwer B, Gabriël S, Basáñez MG (2019)  
561 **Strategies for tackling *Taenia solium* taeniosis/cysticercosis: A systematic review and comparison of**  
562 **transmission models, including an assessment of the wider Taeniidae family transmission models**  
563 *PLoS Neglected Tropical Diseases* **13**:e0007301. doi : 10.1371/journal.pntd.0007301.

- 564 Dixon MA, Winskill P, Harrison WE, Whittaker C, Schmidt V, Sarti E, Bawm S, Dione MM, Thomas LF,  
565 Walker M, Basáñez MG (2020) **Force-of-infection of *Taenia solium* porcine cysticercosis: a modelling  
566 analysis to assess global incidence and prevalence trends.** *Scientific Reports* **10**(1):17637. doi:  
567 10.1038/s41598-020-74007-x.
- 568 Dixon MA, Winskill P, Harrison WE, Basáñez MG (2021) ***Taenia solium* taeniasis/cysticercosis: From  
569 parasite biology and immunology to diagnosis and control** *Advances in Parasitology* **112**:133-217.  
570 doi: 10.1016/bs.apar.2021.03.003.
- 571 Dorny P, Vercammen F, Brandt J, Vansteenkiste W, Berkvens D, Geerts S (2000) **Sero-epidemiological  
572 study of *Taenia saginata* cysticercosis in Belgian cattle** *Veterinary Parasitology* **88**:43–9. doi:  
573 10.1016/s0304-4017(99)00196-x
- 574 Edia-asuke AU, Inabo HI, Mukaratirwa S, Umoh VJ, Whong CMZ, Asuke S, Ella EE (2015)  
575 **Seroprevalence of human cysticercosis and its associated risk factors among humans in areas of  
576 Kaduna metropolis, Nigeria** *Journal Infectious Developing Countries* **9**:799–805. doi:  
577 10.3855/jidc.5415
- 578 Flórez Sánchez AC, Pastrán SM, Vargas NS, Beltrán M, Enriquez Y, Peña AP, Villarreal A, Salamanca L,  
579 Rincón E, Garzón IP, Muñoz L, Guasmayan L, Valencia C, Parra S, Hernandez N (2013) **Cisticercosis en  
580 Colombia. Estudio de seroprevalencia 2008-2010** *Acta Neurológica Colombiana* **29**(2):73–86. ISSN  
581 0120-8748.
- 582 Furrows SJ, McCroddan J, Bligh WJ, Chiodini P (2006) **Lack of specificity of a single positive 50-kDa  
583 band in the electroimmunotransfer blot (EITB) assay for cysticercosis** *Clinical Microbiology and  
584 Infection* **12**(5):459–62. doi: 10.1111/j.1469-0691.2006.01381.x
- 585 Gabriël S, Dorny P, Mwape KE, Trevisan C, Braae UC, Magnussen P, Thys S, Bulaya C, Phiri IK, Sikasunge  
586 CS, Makungu C, Afonso S, Nicolau Q, Johansen MV (2017) **Control of *Taenia solium***

- 587 **taeniasis/cysticercosis: The best way forward for sub-Saharan Africa?** *Acta Tropica* **165**:252–60. doi:  
588 10.1016/j.actatropica.2016.04.010.
- 589 Galipó E, Dixon MA, Fronterre C, Cucunubá ZM, Basáñez MG, Stevens K, Flórez Sánchez AC, Walker M  
590 (2021) **Spatial distribution and risk factors for human cysticercosis in Colombia** *Parasites & Vectors*  
591 **27**;14(1):590. doi: 10.1186/s13071-021-05092-8.
- 592 Gambhir M, Basáñez MG, Burton MJ, Solomon AW, Bailey RL, Holland MJ, Blake IM, Donnelly CA, Jabr  
593 I, Mabey DC, Grassly NC (2009) **The development of an age-structured model for trachoma**  
594 **transmission dynamics, pathogenesis and control** *PLoS Neglected Tropical Diseases* **3**:e462–e462.  
595 doi: 10.1371/journal.pntd.0000462.
- 596 García HH, Gonzalez AE, Gilman RH, Palacios LG, Jimenez I, Rodriguez S, Verastegui M, Wilkins P, Tsang  
597 VC; Cysticercosis Working Group in Peru (2001) **Short report: transient antibody response in *Taenia***  
598 ***solium* infection in field conditions—a major contributor to high seroprevalence** *American Journal of*  
599 *Tropical Medicine and Hygiene* **65**:31–32. doi: 10.4269/ajtmh.2001.65.31.
- 600 García H, Gilman R, Gonzalez A, Verastegui M, Rodriguez S, Gadivia C, Tsang VCW, Falcon N, Lescano  
601 AG, Moulton LH, Bernal T, Tovar M, Cysticercosis Working Group in Perú (2003a) **Hyperendemic**  
602 **Human and Porcine *Taenia Solium* Infection in Perú** *American Journal of Tropical Medicine and*  
603 *Hygiene* **68**:268–75. PMID: 12685628.
- 604 García HH, Gonzalez AE, Evans CAW, Gilman RH, Cysticercosis Working Group in Perú (2003b) ***Taenia***  
605 ***solium* cysticercosis** *Lancet* **362**:547–56. doi: 10.1016/S0140-6736(03)14117-7
- 606 García HH, Rodriguez S, Friedland JS Cysticercosis Working Group in Perú (2014) **Immunology of**  
607 ***Taenia solium* taeniasis and human cysticercosis** *Parasite Immunology* **36**(8):388-96. doi:  
608 10.1111/pim.12126.
- 609 Gomes I, Veiga M, Embiruçu EK, Rabelo R, Mota B, Meza-Lucas A, Tapia-Romero R, Carillo-Becerril BL,  
610 Alcantara-Anguiano I, Correa D, Melo A (2002) **Taeniasis and cysticercosis prevalence in a small**

- 611 **village from Northeastern Brazil** *Arquivos de Neuro-Psiquiatria* **60**:93–103. doi: 10.1590/s0004-  
612 282x2002000200006
- 613 Gonzalez AE, Gilman R, Garcia H, Lopez T (2002) **Use of a simulation model to evaluate control**  
614 **programmes against *Taenia solium* cysticercosis** In: Singh G, Prabhakar S, editors. *Taenia solium*  
615 *Cysticercosis From Basic to Clinical Science First*. London: CAB International. p. 437–48.
- 616 Grenfell BT, Anderson RM (1985) **The estimation of age-related rates of infection from case**  
617 **notifications and serological data** *The Journal of Hygiene (London)* **95**(2):419-36. doi:  
618 10.1017/s0022172400062859.
- 619 Gripper LB, Welburn SC (2017) **The causal relationship between neurocysticercosis infection and the**  
620 **development of epilepsy—A systematic review** *Infect Disease of Poverty* **6**:31. doi: 10.1186/s40249-  
621 017-0245-y.
- 622 Hamley JID, Milton P, Walker M, Basáñez MG (2019) **Modelling exposure heterogeneity and density**  
623 **dependence in onchocerciasis using a novel individual-based transmission model, EPIONCHO-IBM:**  
624 **Implications for elimination and data needs** *PLoS Neglected Tropical Diseases* **13**(12):e0007557.  
625 doi:10.1371/journal.pntd.0007557
- 626 Hancock K, Pattabhi S, Whitfield FW, Yushak ML, Lane WS, Garcia HH, Gonzalez AE, Gilman RH, Tsang  
627 VCW (2006) **Characterization and cloning of T24, a *Taenia solium* antigen diagnostic for cysticercosis**  
628 *Molecular and Biochemical Parasitology* **147**:109–17. doi : 10.1016/j.molbiopara.2006.02.004
- 629 Harrison LJS, Joshua GWP, Wright SH, Parjhouse RME (1989) **Specific detection of circulating**  
630 **surface/secreted glycoproteins of viable cysticerci in *Taenia saginata* cysticercosis** *Parasite*  
631 *Immunology* **11**:351–70. doi:10.1111/j.1365-3024.1989.tb00673.x
- 632 Havelaar AH, Kirk MD, Torgerson PR, Gibb HJ, Hald T, Lake RJ, Praet N, Bellinger DC, de Silva NR,  
633 Gargouri N, Speybroeck N, Cawthorne A, Mathers C, Stein C, Angulo FJ, Devleeschauwer B; World  
634 Health Organization Foodborne Disease Burden Epidemiology Reference Group 2010 (2015) **World**



- 635 **Health Organization Global Estimates and Regional Comparisons of the Burden of Foodborne**  
636 **Disease in 2010** *PLoS Medicine* 12(12):e1001923. doi: 10.1371/journal.pmed.1001923.
- 637 Holt HR, Inthavong P, Khamlome B, Blaszak K, Keokamphe C, Somoulay V, Phongmany A, Burr PA,  
638 Graham K, Allen J, Donnelly B, Blacksell SD, Unger F, Grace D, Alonso S, Gilbert J (2016) **Endemicity of**  
639 **Zoonotic Diseases in Pigs and Humans in Lowland and Upland Lao PDR: Identification of Socio-**  
640 **cultural Risk Factors** *PLoS Neglected Tropical Diseases* 12:10(4):e0003913. doi:  
641 10.1371/journal.pntd.0003913
- 642 Jayaraman T, Prabhakaran V, Babu P, Raghava MV, Rajshekhar V, Dorny P, Muliyl J, Oommen A (2011)  
643 **Relative seroprevalence of cysticercus antigens and antibodies and antibodies to *Taenia ova* in a**  
644 **population sample in south India suggests immunity against neurocysticercosis.** *Transactions of The*  
645 *Royal Society of Tropical Medicine and Hygiene* 105:153–9. doi: 10.1016/j.trstmh.2010.10.007
- 646 Johansen MV, Trevisan C, Gabriël S, Magnussen P, Braae UC (2017) **Are we ready for *Taenia solium***  
647 **cysticercosis elimination in sub-Saharan Africa?** *Parasitology* 144:59–64. doi:  
648 10.1017/S0031182016000500.
- 649 Kanobana K, Praet N, Kabwe C, Dorny P, Lukanu P, Madinga J, Mitashi P, Verwijs M, Lutumba P, Olman  
650 K (2011) **High prevalence of *Taenia solium* cysticercosis in a village community of Bas-Congo,**  
651 **Democratic Republic of Congo** *International Journal Parasitology* 41:1015–8. doi:  
652 10.1016/j.ijpara.2011.06.004.
- 653 Kojic EM, White AC Jr (2003) **A positive enzyme-linked immunoelectrotransfer blot assay result for a**  
654 **patient without evidence of cysticercosis** *Clinical Infectious Diseases* 36(1):e7–9. doi:  
655 10.1086/344445.
- 656 Lescano AG, Garcia HH, Gilman RH, Gavidia CM, Tsang VCW, Rodriguez S, Moulton LH, Villaran MV,  
657 Montano SM, Gonzalez AE (2009) ***Taenia solium* Cysticercosis Hotspots Surrounding Tapeworm**

- 658 **Carriers: Clustering on Human Seroprevalence but Not on Seizures** *PLoS Neglected Tropical Diseases*  
659 **3**(1):e371. doi: 10.1371/journal.pntd.0000371
- 660 Lightowers MW, Donadeu M, Elaiyaraja M, Maithal K, Kumar KA, Gauci CG, Firestone SM, Sarasola P,  
661 Rowan TG (2016a) **Anamnestic responses in pigs to the *Taenia solium* TSOL18 vaccine and**  
662 **implications for control strategies** *Parasitology* **143**:416–20. doi: 10.1017/S0031182016000202
- 663 Lightowers MW, Garcia HH, Gauci CG, Donadeu M, Abela-Ridder B (2016b) **Monitoring the outcomes**  
664 **of interventions against *Taenia solium*: options and suggestions** *Parasite Immunology* **38**:158–69.  
665 doi: 10.1111/pim.12291
- 666 López M, Murillo C, Sarria N, Nicholls R, Corredor A (1988) **Estandarización y evaluación de la prueba**  
667 **de ELISA para la detección de anticuerpos en LCR y suero en neurocisticercosis** *Acta Neurológica*  
668 *Colombiana* **4**:164–9.
- 669 Madinga J, Kanobana K, Lukanu P, Abatih E, Baloji S, Linsuke S Praet N, Kapinga S, Polman K, Lutumba  
670 P, Speybroeck N, Dorny P, Harrison W, Gabriël S (2017) **Geospatial and age-related patterns of *Taenia***  
671 ***solium* taeniasis in the rural health zone of Kimpese , Democratic Republic of Congo** *Acta Tropica*  
672 **165**:100–9. doi:10.1016/j.actatropica.2016.03.013
- 673 Muench H (1943) **Derivation of Rates from Summation Data by the Catalytic Curve** *Journal of the*  
674 *American Statistics Association* **29**:25–38. doi: 10.2307/2278457
- 675 Moro PL, Lopera L, Bonifacio N, Gilman RH, Silva B, Verastegui M, Gonzalez A, Garcia HH, Cabrera L,  
676 Cysticercosis Working Group in Peru (2003) ***Taenia solium* infection in a rural community in the**  
677 **Peruvian Andes** *Annals of Tropical Medicine and Parasitology* **97**:373–9.  
678 10.1179/000349803235002371
- 679 Mwape KE, Phiri IK, Praet N, Muma JB, Zulu G, van den Bossche P, de Deken R, Speybroeck N, Dorny  
680 P, Gabriël S (2012) ***Taenia solium* infections in a rural area of Eastern Zambia-A community based**  
681 **study** *PLoS Neglected Tropical Diseases* **6**(3):e1594. doi: 10.1371/journal.pntd.0001594

682 Mwape KE, Phiri IK, Praet N, Speybroeck N, Muma JB, Dorny P, Gabriël S (2013) **The incidence of**  
683 **human cysticercosis in a rural community of eastern Zambia** *PLoS Neglected Tropical Diseases* **7**:  
684 e2142.

685 Mwape KE, Phiri IK, Praet N, Dorny P, Muma JB, Zulu G, Speybroeck N, Gabriël S (2015) **Study and**  
686 **Ranking of Determinants of *Taenia solium* Infections by Classification Tree Models** *American Journal*  
687 *of Tropical Medicine and Hygiene* **92**:56–63. doi: 10.4269/ajtmh.13-0593.

688 Ng-Nguyen D, Stevenson MA, Dorny P, Gabriël S, Vo TV, Nguyen VT, Phan TV, Hii SF, Traub RJ (2017)  
689 **Comparison of a new multiplex real-time PCR with the Kato Katz thick smear and copro-antigen**  
690 **ELISA for the detection and differentiation of *Taenia* spp. in human stools** *PLoS Neglected Tropical*  
691 *Diseases* **7**;11(7):e0005743.

692 Nguekam JP, Zoli AP, Zogo PO, Kamga ACT, Speybroeck N, Dorny P, Brandt J, Losson B, Geerts S (2003)  
693 **A seroepidemiological study of human cysticercosis in West Cameroon** *Tropical Medicine and*  
694 *International Health* **8**:144–9. doi: 10.1046/j.1365-3156.2003.01000.x.

695 Noh J, Rodriguez S, Lee Y-M, Handali S, Gonzalez AE, Gilman RH, Tsand VCW, Garcia HH, Wilkin PP  
696 (2014) **Recombinant protein-and synthetic peptide-based immunoblot test for diagnosis of**  
697 **neurocysticercosis** *Journal of Clinical Microbiology* **52**(5):1429–34. doi: 10.1128/JCM.03260-13

698 NTD Modelling Consortium Onchocerciasis Group (2019) **The World Health Organization 2030 goals**  
699 **for onchocerciasis: Insights and perspectives from mathematical modelling: NTD Modelling**  
700 **Consortium Onchocerciasis Group** *Gates Open Research* **26**;3:1545. doi:  
701 10.12688/gatesopenres.13067.1.

702 Prost, A., Hervouet, J. P. & Thylefors, B (1979) **Les niveaux d'endémicité dans l'onchocercose** *Bulletin*  
703 *of the World Health Organization* **57**, 655–662.


704 R Core Team (2021). **R: A language and environment for statistical computing**. R version 4.0.5. R  
705 Foundation for Statistical Computing, Vienna, Austria. URL : <https://www.R-project.org/>.

- 706 Sahlu I, Carabin H, Ganaba R, Preux PM, Cisse AK, Tarnagda Z, Gabriël S, Dermauw V, Dorny P, Bauer  
707 C, Milogo A (2019) **Estimating the association between being seropositive for cysticercosis and the**  
708 **prevalence of epilepsy and severe chronic headaches in 60 villages of rural Burkina Faso** *PLoS*  
709 *Neglected Tropical Diseases* **13**:e0007101. doi: 10.1371/journal.pntd.0007101
- 710 Smith JL, Flueckiger RM, Hooper PJ, Polack S, Cromwell EA, Palmer SL, Emerson PM, Mabey DCW,  
711 Solomon AW, Haddad D, Brooker SJ (2013) **The geographical distribution and burden of trachoma in**  
712 **Africa.** *PLoS Neglected Tropical Diseases* **7**: e2359. doi: 10.1371/journal.pntd.0002359.
- 713 Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A (2002) **Bayesian measures of model complexity**  
714 **and fit** *Journal of the Royal Statistical Society Series B* **64**, 583–639. doi: 10.1111/1467-9868.00353
- 715 Theis JH, Goldsmith RS, Flisser A, Koss J, Chionino C, Plancarte A (1994) **Detection by immunoblot**  
716 **assay of antibodies to *Taenia solium* cysticerci in sera from residents of rural communities and from**  
717 **epileptic patients in Bali, Indonesia** *The Southeast Asian Journal of Tropical Medicine and Public*  
718 *Health* **25**(3):464-8. PMID: 7777908.
- 719 Thomas LF, Cook EAJ, Fèvre EM, Rushton J (2019) **Control of *Taenia solium*; A Case for Public and**  
720 **Private Sector Investment** *Frontiers in Veterinary Science* **6**:176. doi:10.3389/fvets.2019.00176
- 721 Tsang VC, Brand JA, Boyer AE (1989) **An enzyme-linked immunoelectrotransfer blot assay and**  
722 **glycoprotein antigens for diagnosing human cysticercosis (*Taenia solium*)** *The Journal of Infectious*  
723 *Diseases* **159**:50–9. doi: 10.1093/infdis/159.1.50
- 724 Wardrop NA, Thomas LF, Atkinson PM, de Glanville WA, Cook EAJ, Wamae CN, Gabriël S, Dorny P,  
725 Harrison LJS, Fèvre EM (2015) **The Influence of Socio-economic, Behavioural and Environmental**  
726 **Factors on *Taenia* spp. Transmission in Western Kenya: Evidence from a Cross-Sectional Survey in**  
727 **Humans and Pigs** *PLoS Neglected Tropical Diseases* **7**:9(12):e0004223. doi:  
728 10.1371/journal.pntd.0004223.

- 729 Weka RP, Ikeh EI, Kamani J (2013) **Seroprevalence of antibodies (IgG) to *Taenia solium* among pig**  
730 **rearsers and associated risk factors in Jos metropolis, Nigeria** *The Journal of Infection in Developing*  
731 *Countries* **15**:7(2):67-72. doi: 10.3855/jidc.2309
- 732 Welburn SC, Beange I, Ducrotoy MJ, Okello AL (2015) **The neglected zoonoses--the case for integrated**  
733 **control and advocacy** *Clinical Microbiology and Infection* **21**(5):433-43. doi:  
734 10.1016/j.cmi.2015.04.011.
- 735 Wilkins PP, Allan JC, Verastegui M, Acosta M, Eason AG, Garcia HH, Gonzalez AE, Gilman RH, Tsang VC  
736 (1999) **Development of a serologic assay to detect *Taenia solium* taeniasis** *American Journal of*  
737 *Tropical Medicine and Hygiene* **60**:199–204. doi: 10.4269/ajtmh.1999.60.199
- 738 World Health Organization, 2020 (2020). **Ending the Neglect to Attain the Sustainable Development**  
739 **Goals: A Road Map for Neglected Tropical Diseases 2021–2030**. WHO, Geneva, Switzerland, pp. 63.  
740 Available: [https://www.who.int/neglected\\_diseases/WHONTD-roadmap-2030/en/](https://www.who.int/neglected_diseases/WHONTD-roadmap-2030/en/).
- 741


## Human taeniasis

### a) Simple model (antibody seroconversion or infection acquisition only)



$$p(a) = 1 - e^{-\lambda(a)}$$


### b) Reversible model (antibody seroconversion & seroreversion; or infection acquisition & loss)



$$p(a) = \frac{\lambda}{\lambda + \rho} \left[ 1 - e^{-(\lambda + \rho)(a)} \right]$$


## Human cysticercosis

### c) Simple model (antibody seroconversion; or infection acquisition only)



$$p(a) = 1 - e^{-\lambda(a)}$$


### d) Reversible model (antibody seroconversion & seroreversion; or infection acquisition & loss)




$$p(a) = \frac{\lambda}{\lambda + \rho} \left[ 1 - e^{-(\lambda + \rho)(a)} \right]$$

medRxiv preprint doi: <https://doi.org/10.1101/2022.02.22.22270710>; this version posted February 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


Human taeniasis model parameters (a & b)		Human cysticercosis model parameters (c & d)		
	$\lambda$ (year <sup>-1</sup> )	$\rho$ (year <sup>-1</sup> )	$\lambda$ (year <sup>-1</sup> )	$\rho$ (year <sup>-1</sup> )
Antibody	Force of seroconversion ( $\lambda_{sero}$ ): rate at which humans antibody seroconvert, which are raised in serum against <i>T. solium</i> adult tapeworm excretory-secretory (ES) products, indicative of active or past infection (Lightowlers et al., 2016a).	Rate of antibody seroreversion ( $\rho_{sero}$ ).	Force of seroconversion ( $\lambda_{sero}$ ): rate at which humans antibody seroconvert following exposure to <i>T. solium</i> infective stages (eggs via indirect environmental transmission) and/or infection with <i>T. solium</i> metacystode.	Rate of antibody seroreversion ( $\rho_{sero}$ ).
Antigen	Force of infection acquisition ( $\lambda_{inf}$ ): rate at which humans develop an immature/mature adult tapeworm infection indicated by copro-antigen positivity.	Rate at which humans lose adult tapeworm infection indicated by becoming copro-antigen negative ( $\rho_{inf}$ ).	Force of infection acquisition ( $\lambda_{inf}$ ): rate at which humans acquire <i>T. solium</i> metacystode infection indicated by antigen positivity.	Rate at which humans clear <i>T. solium</i> metacystode infection, indicating by becoming antigen negative ( $\rho_{inf}$ ).

**a**



**Model fitted to data** — Model with infection acquisition — Model with infection acquisition and infection loss

**b**

**Model fitted to data** — Model with antibody seroconversion — Model with antibody seroconversion and seroreversion



**a**


**Model fitted to data** ■ Model with antibody seroconversion and seroreversion






**b****c**



**Model fitted to data** ■ Model with antibody seroconversion









**a****b**

**Model selected** • Reversible ▲ Simple **Diagnostic** — Antibody — Antigen